Mr Anthony George Pennant Jr, LMFT | |
211 Paris Ave Ste 1, Brooklawn, NJ 08030-2526 | |
(267) 997-8744 | |
Not Available |
Full Name | Mr Anthony George Pennant Jr |
---|---|
Gender | Male |
Speciality | Marriage & Family Therapist |
Location | 211 Paris Ave Ste 1, Brooklawn, New Jersey |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1811380884 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
106H00000X | Marriage & Family Therapist | MF000829 (Pennsylvania) | Primary |
Mailing Address | Practice Location Address |
---|---|
Mr Anthony George Pennant Jr, LMFT 211 Paris Ave Ste 1, Brooklawn, NJ 08030-2526 Ph: (267) 997-8744 | Mr Anthony George Pennant Jr, LMFT 211 Paris Ave Ste 1, Brooklawn, NJ 08030-2526 Ph: (267) 997-8744 |
News Archive
Health, family and romance problems appear to be the particular life stressors most associated with increased risk for using opioids to cope, and individuals with low self-esteem appear to be at risk for these connections, according to a new paper including researchers at Binghamton University, State University at New York.
Researchers at UmeƄ University and Region Norrbotten in Sweden have studied health trends among women and men aged 25-34 from 1990-2014. In 1990, 8.5 percent of women self-rated their health as being worse than peers in their own age group.
Inova Diagnostics, a worldwide leader in autoimmune diagnostic reagents and systems for the clinical laboratory, is pleased to announce the US Food and Drug Administration clearance of QUANTA Lite Calprotectin Extended Range, an assay which aids in the diagnosis of Inflammatory Bowel Disease (IBD), and can help differentiate IBD from Irritable Bowel Syndrome (IBS).
A new report by an independent health analyst, says hospital patients are at greater risk of dying at weekends.
Astellas Pharma Inc. and Ocata Therapeutics, Inc., a biotechnology company focused on the research and development of new therapies in the field of regenerative medicine, primarily cell therapy addressing unmet medical needs in ophthalmology patients, announced today that they have entered into a definitive agreement.
› Verified 3 days ago